Chiltern Early Phase is one of the oldest clinical pharmacology units specializing First-In-Man and Phototoxicity studies in the UK. Established in 1982, our team has performed more than 700 studies, covering a wide range of pharmacokinetic and pharmacodynamic studies in all the major therapeutic areas and routes of administration.

In addition to First-In-Man and Phototoxicity studies, we have experience in:

• Drug-drug interaction studies
• Proof of concept / Efficacy studies
• Bioequivalence/bioavailability and food effect studies
• TQT studies
• ADME studies
• Japanese bridging studies

Chiltern’s dedicated Early Phase team of project managers, physicians, recruitment staff and scientists approach every study with five criteria in mind:

• Safety
• Precision
• Quality
• Compliance
• Timeliness

Our team has worked closely with UK National Research Ethics Service (NRES) and possesses significant experience in supplying data to the regulatory authorities in Europe, Japan and USA.

As a business unit within a full service CRO, our clients benefit from a wide range of Chiltern's in-house support services such as data management, biostatistics, medical writing, clinical monitoring, quality management, pharmacovigilance, regulatory support and contract staffing.